dc.contributor.author | O'Carrigan, B | |
dc.contributor.author | Lim, JSJ | |
dc.contributor.author | Jalil, A | |
dc.contributor.author | Harris, SJ | |
dc.contributor.author | Papadatos-Pastos, D | |
dc.contributor.author | Banerji, U | |
dc.contributor.author | Lopez, J | |
dc.contributor.author | de Bono, JS | |
dc.contributor.author | Yap, TA | |
dc.date.accessioned | 2018-10-24T08:17:08Z | |
dc.date.issued | 2018-10-15 | |
dc.identifier.citation | British journal of cancer, 2018, 119 (8), pp. 922 - 927 | |
dc.identifier.issn | 0007-0920 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/2906 | |
dc.identifier.eissn | 1532-1827 | |
dc.identifier.doi | 10.1038/s41416-018-0290-8 | |
dc.description.abstract | Background Greater understanding of the molecular classification of breast cancer has permitted the development of rational drug design strategies. In a phase I clinical trial setting, molecular profiling with next-generation sequencing of individual tumour samples has been employed to guide treatment.Methods We conducted a retrospective evaluation of clinical outcomes of patients with metastatic breast cancer (MBC) treated in phase I clinical trials at our institution to assess the benefit of molecularly matched compared to non-matched treatments.Results A total of 97 consecutive patients with MBC were enrolled onto ≥1 trial between 2009 and 2015. Fourteen patients participated in multiple trials, and a total of 113 trial encounters were reviewed in this retrospective study. Eighty-three percent of patients with molecular data available were able to participate in trials matched to molecular aberrations. Patients who were treated on matched studies had improved clinical benefit (RR: 1.80, p = 0.005), progression-free (HR: 0.52, p = 0.003) and overall survival (HR: 0.54, p < 0.001). Treatment was well tolerated with low rates of treatment discontinuation for toxicity (8% overall) that did not differ between groups. No toxicity-related deaths were observed.Conclusions Molecular profiling for MBC patients in a phase I setting is feasible and aids therapeutic decisions with improved patient outcomes. | |
dc.format | Print-Electronic | |
dc.format.extent | 922 - 927 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Breast Neoplasms | |
dc.subject | Receptor, erbB-2 | |
dc.subject | BRCA1 Protein | |
dc.subject | BRCA2 Protein | |
dc.subject | Receptors, Estrogen | |
dc.subject | Antineoplastic Agents | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Disease-Free Survival | |
dc.subject | Retrospective Studies | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Middle Aged | |
dc.subject | England | |
dc.subject | Female | |
dc.subject | Clinical Trials, Phase I as Topic | |
dc.subject | Molecular Targeted Therapy | |
dc.subject | Tertiary Care Centers | |
dc.title | Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre. | |
dc.type | Other | |
rioxxterms.versionofrecord | 10.1038/s41416-018-0290-8 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.licenseref.startdate | 2018-10-15 | |
rioxxterms.type | Other | |
dc.relation.isPartOf | British journal of cancer | |
pubs.issue | 8 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.publication-status | Published | |
pubs.volume | 119 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicine (de Bono Prostate) | en_US |
icr.researchteam | Clinical Pharmacology – Adaptive Therapy | en_US |
icr.researchteam | Medicine Drug Development Unit (de Bono) | en_US |
icr.researchteam | Prostate Cancer Targeted Therapy Group | en_US |
dc.contributor.icrauthor | Yap, Timothy | |
dc.contributor.icrauthor | Banerji, Udai | |
dc.contributor.icrauthor | Lopez, Juanita | |
dc.contributor.icrauthor | De Bono, Johann | |
dc.contributor.icrauthor | Turner, Lydia | |